Insider trade

CFO sold ~$322K of UTHR shares in the open market

Traded Apr 9, 2026 · Filed Apr 11, 2026

Why it stands out

The CFO of United Therapeutics sold $322K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CFO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$321,926

Shares × reported transaction price

Timing vs results

43 days after results of Feb 25, 2026, 27 days before results of May 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−0.7%	+3.3%	−4.0%
30 days	+0.3%	+8.2%	−7.9%
90 days	−7.3%	+9.2%	−16.5%

Past results only. Not a forecast.

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
This transaction was executed in multiple trades at prices ranging from $574.18 to $575.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed 5mo ago

Traded May 7 · filed 4 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 5mo ago

Scheduled in advanceFiled 5mo ago